Want to see IN:METROPOLIS full AI Analyst Report?
Top Page
Metropolis Healthcare Ltd.
(METROPOLIS)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹570.00
▲(0.68% Upside)
Action:Downgraded
Date:08/17/26
The score is supported primarily by strong financial fundamentals (re-accelerating revenue growth, positive and improving free cash flow, and low leverage). This is partially offset by weak near-term technicals (below key moving averages with negative MACD) and a rich valuation (high P/E with low dividend yield).
Positive Factors
Revenue re-acceleration
A stronger top-line trajectory indicates improving demand for diagnostic services and supports operating scale. Sustained volume growth across routine and specialized testing can reinforce Metropolis's market reach over the next several quarters.
Negative Factors
Profitability below prior peak
Earnings have not kept pace with the expanded revenue base, indicating that cost control, pricing or service mix may be limiting operating leverage. Persistent margin variability could constrain the durability of future profit growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue re-acceleration
A stronger top-line trajectory indicates improving demand for diagnostic services and supports operating scale. Sustained volume growth across routine and specialized testing can reinforce Metropolis's market reach over the next several quarters.
Read all positive factors
Metropolis Healthcare Ltd. (METROPOLIS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹119.94B
Dividend Yield0.34%
Average Volume (3M)57.97K
Price to Earnings (P/E)59.8
Beta (1Y)0.61
Revenue Growth21.80%
EPS Growth31.84%
CountryIN
Employees4,484
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)9.73
Shares Outstanding207,387,570
10 Day Avg. Volume150,896
30 Day Avg. Volume57,971
Financial Highlights & Ratios
PEG Ratio1.54
Price to Book (P/B)5.93
Price to Sales (P/S)5.45
P/FCF Ratio30.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.36
Revenue Forecast (FY)₹19.03B
Metropolis Healthcare Ltd. Business Overview & Revenue Model
Company Description
Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its c...
How the Company Makes Money
Metropolis Healthcare primarily makes money by charging fees for diagnostic testing and related laboratory services. Its key revenue streams typically include: (1) business-to-consumer (B2C) revenue from walk-in and home-collection customers who p...
Metropolis Healthcare Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.10B | 16.46B | 13.31B | 12.08B | 11.48B | 12.28B |
| Gross Profit | 9.66B | 7.87B | 10.28B | 9.38B | 8.74B | 9.31B |
| EBITDA | 4.36B | 4.17B | 2.16B | 2.18B | 2.36B | 3.07B |
| Net Income | 2.02B | 1.90B | 1.45B | 1.28B | 1.43B | 2.14B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 21.38B | 18.67B | 15.55B | 15.02B | 15.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.03B | 2.03B | 1.18B | 1.24B | 1.20B | 1.81B |
| Total Debt | 0.00 | 2.32B | 2.04B | 1.97B | 2.66B | 3.79B |
| Total Liabilities | -15.25B | 6.13B | 5.33B | 4.56B | 5.11B | 6.42B |
| Stockholders Equity | 15.25B | 15.13B | 13.31B | 10.96B | 9.88B | 8.86B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.99B | 2.19B | 2.00B | 1.94B | 2.23B |
| Operating Cash Flow | 0.00 | 3.50B | 2.63B | 2.64B | 2.47B | 2.53B |
| Investing Cash Flow | 0.00 | -2.18B | -2.01B | -894.12M | 467.94M | -7.38B |
| Financing Cash Flow | 0.00 | -1.20B | -866.34M | -1.81B | -2.92B | 1.63B |
Metropolis Healthcare Ltd. Technical Analysis
Positive
566.15
Price Trends
568.79
Positive
544.82
Positive
507.71
Positive
Market Momentum
5.78
Negative
55.02
Neutral
49.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Positive. The current price of 566.15 is below the 20-day moving average (MA) of 568.35, below the 50-day MA of 568.79, and above the 200-day MA of 507.71, indicating a bullish trend. The MACD of 5.78 indicates Negative momentum. The RSI at 55.02 is Neutral, neither overbought nor oversold. The STOCH value of 49.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:METROPOLIS.
Metropolis Healthcare Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹90.84B | 33.20 | ― | 1.64% | 21.09% | 65.51% | |
76 Outperform | ₹28.77B | 35.04 | ― | 0.32% | 14.22% | 7.17% | |
74 Outperform | ₹319.18B | 58.95 | ― | 0.84% | 14.29% | 5.55% | |
71 Outperform | ₹154.19B | 82.45 | ― | 0.13% | 20.18% | 24.71% | |
61 Neutral | ₹18.26B | 18.18 | ― | 0.36% | 10.19% | 20.99% | |
59 Neutral | ₹119.94B | 59.82 | ― | 0.34% | 21.80% | 31.84% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:METROPOLIS
Metropolis Healthcare Ltd.
581.75
49.36
9.27%
IN:KRSNAA
Krsnaa Diagnostics Limited
547.15
-290.50
-34.68%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,911.55
341.96
21.79%
IN:THYROCARE
Thyrocare Technologies Ltd
569.10
143.97
33.87%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,503.35
420.00
38.77%
IN:VIMTALABS
Vimta Labs Limited
626.30
-194.27
-23.68%
Metropolis Healthcare Ltd. Corporate Events
Metropolis Healthcare Q1FY27 Update Shows Double-Digit Growth and Margin Gains
Jul 5, 2026
Metropolis Healthcare reported about 16% year-on-year revenue growth in the June 2026 quarter, driven primarily by higher patient volumes and improved realization from a favorable product mix. The TruHealth wellness and specialty businesses emerge...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.